21254 ⎘
Medicinal preparations containing active ingredients not provided for in groups -
Sub-classes:Sugar Free Soft Chew Tablets
#2COMPOSITION FOR TREATING IL-6-RELATED DISEASES
#3METHODS AND COMPOSITIONS FOR CENTRAL NERVOUS SYSTEM (CNS) DRUG DELIVERY AND TREATMENT
#4COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
#5TREATMENT COMPOSITION FOR INHIBITING SYSTEMIC SCLEROSIS VIMENTIN MUTANT PROTEIN ACTIVITY BY USING STAT6 INHIBITOR
#6COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
#7PHARMACEUTICAL COMPOSITION CONTAINING CBFbeta-EXPRESSING VASCULAR SMOOTH MUSCLE CELLS OR CULTURE FLUID THEREOF AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF AGE-RELATED DISEASES
#8PHOSPHATIDYLAMINE COMPOUNDS INCLUDING A PLURALITY OF TERTIARY AMINO GROUP STRUCTURES AND COMPOSITIONS THEREOF
#9PREDICTION AND MONITORING OF IMMUNOTHERAPY IN CANCER
#10COMPOSITIONS AND SYNERGISTIC METHODS FOR TREATING INFECTIONS
#11IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS
#12BIOMARKERS IN PANCREATIC CANCER
#13COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
#14Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent
#15NEW SPLICE VARIANT ISOFORM OF VEGF
#16METHOD TO ASSIST IN SCREENING FOR LATE RECURRENCE OF ER+ BREAST CANCER, AND METHOD FOR SCREENING THERAPEUTIC DRUGS
#17Control of Cellular Redox Levels
#18LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF
#19BORRELIA BURGDORFERI PEPTIDOGLYCAN DETECTION METHODS
#20METHODS AND COMPOSITIONS FOR PROGNOSIS AND TREATMENT OF DILATED CARDIOMYOPATHY AND HEART FAILURE
#21"Good" buffer-based cationic lipids
#22COMPOSITION FOR TREATING IL-6-RELATED DISEASES
#23LACRIMAL DRUG DELIVERY DEVICE
#24SULFIDE-CONTAINING IONIZABLE LIPID AND LIPID NANOPARTICLE INCLUDING THE SAME
#25IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER
#26METHODS OF SELECTING AND TREATING CANCER SUBJECTS THAT ARE CANDIDATES FOR TREATMENT USING INHIBITORS OF A PD-1 PATHWAY
#27BIOMARKERS FOR DISEASE PROGRESSION AND/OR RECURRENCE IN SQUAMOUS CELL CARCINOMA
#28HYPOTONIC GEL-FORMING FORMULATIONS WITH ENHANCED RHEOLOGICAL PROPERTIES
#29METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT
#30TOPICAL DELIVERY COMPOSITIONS COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
#31Base Composition for Tape Agent
#32ANTIBODY-DRUG CONJUGATE
#33CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM
#34PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF ANEURYSMS, DIAGNOSTIC SUPPORT METHOD FOR ANEURYSMS, AND METHOD FOR EVALUATING ANEURYSM THERAPEUTICS
#35COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
#36LACRIMAL DRUG DELIVERY DEVICE
#37TRANSCRIPTIONAL BIOMARKERS FOR RESPONSE TO INNATE IMMUNE ACTIVATORS
#38TOPICAL ANALGESICS
#39Encapsulated biomolecules for intracellular delivery
#40SYSTEM FOR RELEASING A HAEMOSTATIC AGENT INTO THE UTERINE CAVITY
#41COMPOSITION FOR TREATING IL-6-RELATED DISEASES
#42METHODS AND COMPOSITIONS FOR INCREASING N-ACETYLGLUCOSAMINIDASE ACTIVITY IN THE CNS
#43METHOD FOR PRODUCING AN ANTI-LAG-3 ANTIBODY
#44COMPOSITION COMPRISING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR
#45HIGH-DOSE COMPRESSIBLE DOSAGE FORMS MANUFACTURED BY SIMULTANEOUS MELT-COATING AND MELT-GRANULATION OF ACTIVE PHARMACEUTICAL INGREDIENTS
#46METHODS AND COMPOSITIONS FOR TREATING THROMBOTIC DISEASE
#47DETECTION OF KDM1A LOSS OF ACTIVITY FOR DIAGNOSING ENDOCRINE DISORDERS
#48TARGETED THERAPIES IN CANCER
#49TRANSDERMAL SOLVENT SYSTEM AND METHODS OF USE
#50NITROGEN-CONTAINING CATIONIC LIPID AND APPLICATION THEREOF
#51COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
#52Composition for inducing proliferation or accumulation of regulatory T cells
#53Method Of Treatment Of Obesity
#54APPLICATION OF ATP POTASSIUM CHANNEL MODIFIER IN PREPARATION OF ANTI-DIABETIC NEPHROPATHY DRUG
#55METHODS OF DETERMINING RESPONSIVENESS TO CHEMOTHERAPEUTIC COMPOUNDS FOR CANCER THERAPY
#56NOVEL THERAPEUTIC AGENT FOR SEPTICEMIA, AND A METHOD FOR SCREENING FOR SAME
#57TREATMENT OF EXPOSURE TO VESICANTS
#58USE OF SYMPATHETIC ACTIVATION INHIBITOR AND/OR ALPHA 1-ADRENERGIC RECEPTOR INHIBITOR IN PREPARING MEDICINE FOR TREATING DRY EYES
#59STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF
#60ORGANIC COMPOUNDS
#61STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF
#62METHODS FOR PREDICTING RESPONSIVENESS OF PROSTATE CANCER PATIENTS TO PARP INHIBITORS
#63COMPOSITION FOR TREATING IL-6-RELATED DISEASES
#64TNF-ALPHA AND IL-1ALPHA POSITIVE COPD TREATMENT WITH ANTIBIOTICS
#65METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS
#66NOVEL THI-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS AND USE OF SAME
#67COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
#68ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION
#69CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM
#70Methods Of Detecting And Treating Hepatocellular Carcinoma
#71AUTOANTIBODIES RELATED TO IGA NEPHROPATHY
#72PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT
#73CONJUGATES ENHANCING TOTAL CELLULAR ACCUMULATION
#74Lipoprotein complexes and manufacturing and uses thereof
#75GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION
#76NON-CATIONIC SOFT POLYPHENOL NANOCAPSULES FOR EFFECTIVE SYSTEMIC DELIVERY OF SMALL INTERFERING RNA (siRNA) FOR CANCER TREATMENT
#77Lipoprotein complexes and manufacturing and uses thereof
#78AUTOPHAGY ACTIVATOR
#79DETERMINATION AGENT AND DETERMINATION METHOD FOR TAUOPATHY AND DEMENTIA-RELATED DISEASES
#80USES OF MSC IN IMPROVING THROMBOTIC COMPLICATIONS IN COVID-19 PNEUMONIA
#81TEST METHOD, OF DIVIDING BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) INTO SUBTYPES
#82VEGF/DLL4 BINDING AGENTS AND USES THEREOF
#83Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
#84AGENT FOR SUPPRESSING POST-SURGICAL CANCER RECURRENCE AND/OR METASTASIS
#85IMMUNITY ENHANCING AGENT FOR CANCER BY ALLERGIN-1 ANTAGONIST
#86NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF
#87PRETREATMENT DRUG FOR T CELL INFUSION THERAPY FOR IMMUNE-CHECKPOINT INHIBITOR-RESISTANT TUMOR
#88IMMUNE INDUCER
#89PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF
#90Organic compounds
#91COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
#92Base Composition for Tape Agent
#93COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
#94DRUG EFFECTIVE FOR LYMPHOGENOUS DRUG ADMINISTRATING METHOD
#95Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
#96METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT
#97PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT
#98CHEMOPREVENTION USING CONTROLLED- RELEASE FORMULATIONS OF ANTI-INTERLEUKIN 6 AGENTS, SYNTHETIC VITAMIN A ANALOGUES OR METABOLITES, AND ESTRADIOL METABOLITES
#99METHOD FOR TREATING CANCER BY ADMINISTRATION OF ANTIBODIES THAT BIND TO EXTRACELLULAR REGION PORTION OF MCEMP1 PROTEIN
#100Low molecular weight cationic lipids for oligonucleotide delivery
#101CCL5 inhibitors
#102CRYSTALLINE FORMS OF A BIPHENYL COMPOUND
#103LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF
#104METHODS AND COMPOSITIONS OF NEUREGULINS FOR PREVENTING, TREATING OR DELAYING PRESERVED EJECTION FRACTION CARDIAC FAILURE
#105GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF
#106COMPOSITIONS AND SYNERGISTIC METHODS FOR TREATING INFECTIONS
#107MODULATORS OF YAP1 EXPRESSION
#108USE OF IL-17 ANTAGONISTS TO INHIBIT THE PROGRESSION OF STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIC PATIENTS
#109MICROVASCULAR BLOOD FLOW DECREASING AGENT AND USE THEREOF
#110Transdermal solvent system and methods of use
#111DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS
#112METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION
#113LIPID PHARMACEUTICAL PREPARATION AND APPLICATION THEREOF
#114Flavonoid polyphenol drug self-emulsifying composition, preparation method therefor, pharmaceutical composition thereof and application thereof
#115Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy
#116MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER
#117CCL5 inhibitors
#118SECRETORY PROTEIN
#119COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR
#120MODULATION OF CILIOGENESIS
#121COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
#122COMPOSITIONS AND METHODS RELATING TO C5L2
#123Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier
#124Lacrimal drug delivery device
#125Immunoregulatory agent
#126TRICYCLIC SPIRO COMPOUND
#127FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE
#128ANTIBACTERIAL COMPOSITION COMPRISING MICROCIN S AND ANTIBIOTIC
#129METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS
#130Stable antibody-drug conjugate, preparation method therefor, and use thereof
#131METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE
#132COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY
#133Methods and formulations for modulating Lyn kinase activity and treating related disorders
#134Base Composition for Tape Agent
#135ATOPIC DERMATITIS MODEL NON-HUMAN ANIMAL AND USE THEREOF
#136Composition for prophylaxis or treatment of IL-8 related diseases
#137NOVEL TH1-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS, AND USE OF SAME
#138Fine nano-sized medicinal agent and use thereof
#139SYSTEMS AND METHODS FOR ANALYZING PERSISTENT HOMEOSTATIC PERTURBATIONS
#140Methods of preparing a pegylated human IL-11 composition
#141Transdermal solvent system and methods of use
#142Method of treatment of obesity
#143Agent for eliminating senescent cells
#144Sustained drug release sheet for treating nerve injury
#145CCL5 inhibitors
#146Stable antibody-drug conjugate, preparation method therefor, and use thereof
#147METHODS AND FORMULATIONS PROMOTING TISSUE/ORGAN REGENERATION, LONGEVITY AND HEALTHSPAN
#148PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM
#149GEL PATCH
#150Pharmaceutical composition for the treatment of autism
#151Bio-responsive adhesive antibody delivery platform for immunotherapy and preparation method thereof
#152Method for the formulation of oil-soluble substances, and powders obtainable thereof
#153Modulators of YAP1 expression
#154VEGF/DLL4 binding agents and uses thereof
#155ORGANIC COMPOUNDS
#156STATIN-CONTAINING NANOPARTICLE PREPARATION FOR ENHANCING FUNCTION OF STEM CELLS FOR TREATING INFLAMMATORY DISEASE, AND FUNCTIONALLY ENHANCED STEM CELLS CONTAINING SAME FOR TREATING INFLAMMATORY DISEASE
#157S1PR2 ANTAGONISTS FOR TREATING DISEASES INVOLVING ABNORMAL IMMUNE RESPONSES
#158COMPOSITION FOR TREATING IL-6-RELATED DISEASES
#159Composition for treating onychomycosis
#160BLOCKADE OF TIM-1 PATHWAYS and P-SELECTIN PATHWAYS IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE
#161METHOD FOR CHANGING CONDITION OF EYELID OF HAIRLESS ANIMAL
#162Secretory protein
#163Composition comprising poly I:C and LAG-3-IGG fusion protein
#164TRANSCERVICAL TREATMENT OF GYNECOLOGICAL MALIGNANCIES
#165METHOD OF TREATING DEPRESSION
#166METHODS AND COMPOSITIONS OF NEUREGULINS FOR PREVENTING, TREATING OR DELAYING PRESERVED EJECTION FRACTION CARDIAC FAILURE
#167LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE
#168CADAVERIC DERIVED WOUND TREATMENT AND METHOD OF USE
#169Medicine for treating cancer and method for treating cancer
#170Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer
#171MALIGNANT TUMOR TARGET PEPTIDE
#172Echovirus for treatment of tumors
#173Crystalline forms of a biphenyl compound
#174Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
#175ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION
#176PHARMACOTHERAPY FOR PREVENTING OR TREATING GLAUCOMA
#177Composition for ameliorating loss of hair and graying of hair, and use thereof
#178Immunogenic composition for the treatment of cancer
#179Compositions and methods for the treatment of cancer
#180System for adding sensory conditioning cues in a pharmacotherapeutic regimen
#181Compositions and methods for treating CNS disorders
#182Composition for inducing proliferation or accumulation of regulatory T cells
#183Intermediate compound of novel tetrahydronaphthyl urea derivative
#184Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
#185Isotope enhanced ambroxol for long lasting autophagy induction
#186Coloured keratolytic nail lacquer
#187SELECTIVE RELEASE SYSTEM FOR TUMOR THERAPEUTIC AGENTS AND TUMOR DIAGNOSTIC AGENTS AND BIOSENSOR FOR TUMOR TISSUE
#188Low molecular weight cationic lipids for oligonucleotide delivery
#189METHOD FOR SUPPRESSING BRAIN METASTASIS
#190Diagnostic methods for infectious disease using endogenous gene expression
#191Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
#192Screening method for pain suppressor and pharmaceutical composition for prevention or treatment of pain
#193Peptide for inhibiting skin inflammation and composition for preventing or treating skin inflammation containing the same
#194Small molecule inhibitors of MYC and uses thereof
#195FKBP52-TAU INTERACTION AS A NOVEL THERAPEUTICAL TARGET FOR TREATING THE NEUROLOGICAL DISORDERS INVOLVING TAU DYSFUNCTION
#196METHODS OF CANCER TREATMENT
#197CCL5 inhibitors
#198COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS
#199Antibody for treating autoimmune diseases
#200Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
#201Compositions and methods for treating neurodegenerative diseases
#202Tricyclic spiro compound
#203Extract of aerial parts of Maca rich in polyphenols and composition comprising same
#204Benzene, Pyridine, and Pyridazine Derivatives
#205Pyridinone compound and use thereof
#206METHOD FOR TREATING EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE
#207CANCER DIAGNOSIS AND THERAPY
#208Drug effective for lymphogenous drug administrating method
#209PHARMACOTHERAPY FOR PREVENTING OR TREATING GLAUCOMA
#210Compositions, methods and kits to detect herpes simplex virus nucleic acids
#211Peelable nail lacquer
#212Base Composition for Tape Agent
#213Methods of treatment using a branched amino terminal pegylated Il-11 composition
#214Interleukin-11 PEGylation reaction intermediate composition
#215COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY
#216Tetrahydronaphthyl urea derivative
#217Methods and formulations for modulating Lyn kinase activity and treating related disorders
#218BRK inhibitory compound
#219Antibody-drug conjugate having cyclic benzylidene acetal linker
#220GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF
#221Lipoprotein complexes and manufacturing and uses thereof
#222Circulating astrocytes and MFSD2A as biomarkers
#223THIOLATED HYALURONAN-BASED HYDROGELS CROSS-LINKED USING OXIDIZED GLUTATHIONE
#224Composition for inducing proliferation or accumulation of regulatory T cells
#225Composition for inducing proliferation or accumulation of regulatory T cells
#226Anticancer agent comprising HVJ-E and immune checkpoint protein inhibitor
#227Lacrimal drug delivery device
#228Isotope enhanced ambroxol for long lasting autophagy induction
#229CTB-PI polyamide conjugate for activating expression of specific gene
#230RUNX inhibitor
#231Composition for activating neurogenesis
#232Agent for treating retinopathy
#233Antibody binding to TMEM132A, anticancer agent, and cancer test method
#234Pharmaceutical composition for treating and/or preventing cancer
#235Methods for treating autoimmune diseases incorporating an anti-LAG3 antibody
#236COMPOSITIONS AND METHODS RELATING TO C5L2
#237Microvascular blood flow decreasing agent and use thereof
#238Agent for eliminating senescent cells
#239Immunomodulator
#240Atopic dermatitis model non-human animal and use thereof
#241Pulmonary hypertension preventative or therapeutic agent containing component exhibiting selenoprotein P activity-inhibiting effect
#242Malignant tumor target peptide
#243Organic compounds
#244COMPOSITIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS
#245Method of predicting effect of medicinal therapy on cancer
#246Method for treating IL-8-related diseases
#247Methods for cardiomyocyte survival, proliferation or differentiation by NRG-2
#248SALIVARY ABETA42 LEVELS AS PROGNOSTIC INDICATORS FOR ALZHEIMER'S DISEASE
#249Methods of screening using barcoded libraries
#250Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
#251Agent for inducing cell death, agent for suppressing cell proliferation, and pharmaceutical composition used for treatment of disease resulting from abnormal cell proliferation
#252Use of isothiocyanate compounds
#253Statin-containing nanoparticle preparation for enhancing function of stem cells for treating inflammatory disease, and functionally enhanced stem cells containing same for treating inflammatory disease
#254Pharmaceutical composition for the treatment of autism
#255COMPOSITIONS AND METHODS FOR PROGNOSIS OF OVARIAN CANCER
#256PRETREATMENT DRUG FOR T CELL INFUSION THERAPY FOR IMMUNE-CHECKPOINT INHIBITOR-RESISTANT TUMOR
#257Method for treating cancer by administration of antibodies that bind to extracellular region portion of MCEMP1 protein
#258Method of treatment of obesity
#259RGD and transferrin nanoparticle composition
#260Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
#261BIOABSORBABLE SHEET OR FILM
#262Secretory protein
#263Sustained drug release sheet for treating nerve injury
#264Immunogenic peptides of SCD1 protein
#265Tumor cell malignant transformation suppressor and anti-tumor agent
#266VEGF/DLL4 BINDING AGENTS AND USES THEREOF
#267ACAT1 inhibitors for treating cancer
#268Methods and compositions for the prevention and treatment of surgical adhesions
#269Composition for inducing proliferation or accumulation of regulatory T cells
#270Agent for overcoming immunosuppression and use thereof
#271Composition for inducing proliferation or accumulation of regulatory T cells
#272Therapeutic angiogenesis for treating erectile conditions
#273Compositions, methods and kits to detect Herpes Simplex virus nucleic acids
#274Tetrahydronaphthyl urea derivative
#275Drug container
#276P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV)
#277Marine organism-derived extract, compound, and medical composition having niche formation suppressing activity of leukemic stem cells
#278Antagonists of IL-6 to raise albumin and/or lower CRP
#279Methods of treating lung cancer
#280Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same
#281ANTI-INFLUENZA VIRUS AGENT AND SCREENING METHOD FOR ANTI-INFLUENZA VIRUS AGENT
#282GM3-promoted inflammation inhibitor and inflammatory cytokine production inhibitor
#283METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS
#284Modulating permeability of the blood cerebrospinal fluid barrier
#285Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
#286Composition for ameliorating loss of hair and graying of hair, and use thereof
#287Modulation of ciliogenesis
#288Immunoregulatory agent
#289Blood biomarker for use in evaluation of effect of drug therapy on kidney cancer
#290Tricyclic spiro compound
#291METHOD TO INHIBIT ENDOTHELIAL-TO-MESENCHYMAL TRANSITION
#292Method of committed differentiation of human induced pluripotent stem cells into Leydig cells and application of Leydig cells
#293Compositions and methods for the treatment of cancer
#294VEGF/DLL4 binding agents and uses thereof
#295Process for treating glaucoma
#296Replacement of cytotoxic preconditioning before cellular immunotherapy
#297Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
#298Stimulus-responsive micellar carrier
#299Adhesive polymer and medical adhesive patch
#300Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product